Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21. The Food and Drug Administration (FDA) has granted Fast Track ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) after 36 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Efruxifermin improved liver histology, ...

In one of the biggest deals of the waning year, Novo Nordisk A/S is buying Akero Therapeutics Inc. to bolster its metabolic dysfunction-associated steatohepatitis (MASH)-treatment portfolio. In the $5 ...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Please provide your email address to receive an email when new articles are posted on . Among patients with FIB-4 nonalcoholic steatohepatitis at greater risk for progression to end stage liver ...

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic ...

“Patients with type 2 diabetes, many of whom also have NASH with fibrosis, have a significant need for novel therapies that can treat NASH while improving diabetes control and reducing the high risk ...

Among patients with pre-cirrhotic NASH and stage ≥1 fibrosis, 41% of those who received efruxifermin 50 mg and 39% of those who received efruxifermin 28 mg met the primary endpoint of fibrosis ...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics announced promising results from the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for treating pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...